{"page_content": "ESG Report 2023\nDrug Safety and Counterfeit Drugs  \n(continued)\nNumber of fatalities associated with products as reported in \nthe FDA Adverse Event Reporting System  \nSASB: HC-BP-250A.2\nAs of December 31, 2022, no fatalities have been assessed as \nrelated to Agios products (mitapivat & AG-946) as reported in the FDA Adverse Event Reporting System, which can be found here .\nNumber of recalls issued, total units recalled  \nSASB: HC-BP-250A.3\nAgios has not been subject to any FDA recalls.\nNumber of FDA enforcement actions taken in response to \nviolations of current Good Manufacturing Practices (cGMP), by type\n \nSASB: HC-BP-250A.5\nAgios has not had any GMP violations or FDA enforcement actions.\n17", "metadata": {"source": "NASDAQ_AGIO_2022.pdf", "page": 16, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}